Breast cancer metastasis: markers and models (original) (raw)

• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687–1717 (2005). Gives an overview of the results of 194 randomized trials of adjuvant chemotherapy or hormonal therapy among women with early breast cancer.
• Eifel, P. et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J. Natl Cancer Inst. 93, 979–989 (2001). Provides an assessment of available data between January 1995 and July 2000 regarding the use of adjuvant therapy for breast cancer.
  Article CAS PubMed Google Scholar
• Fidler, I. J. & Kripke, M. L. Metastasis results from preexisting variant cells within a malignant tumour. Science 197, 893–895 (1977). The experimental data establish the longstanding model of metastasis, which indicates that metastatic cells are rare and arise late during tumorigenesis.
  Article CAS PubMed Google Scholar
• Milas, L., Peters, L. J. & Ito, H. Spontaneous metastasis: random or selective? Clin. Exp. Metastasis 1, 309–315 (1983).
  Article CAS PubMed Google Scholar
• Giavazzi, R., Alessandri, G., Spreafico, F., Garattini, S. & Mantovani, A. Metastasizing capacity of tumour cells from spontaneous metastases of transplanted murine tumours. Br. J. Cancer 42, 462–472 (1980).
  Article CAS PubMed PubMed Central Google Scholar
• Mantovani, A., Giavazzi, R., Alessandri, G., Spreafico, F. & Garattini, S. Characterization of tumour lines derived from spontaneous metastases of a transplanted murine sarcoma. Eur. J. Cancer 17, 71–76 (1981).
  Article CAS PubMed Google Scholar
• van't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530–536 (2002). Shows that a 70-gene expression profile of primary breast tumours can predict the later appearance or absence of distant metastases.
  Article CAS Google Scholar
• van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999–2009 (2002).
  Article CAS PubMed Google Scholar
• Ramaswamy, S., Ross, K. N., Lander, E. S. & Golub, T. R. A molecular signature of metastasis in primary solid tumours. Nature Genet. 33, 49–54 (2003).
  Article CAS PubMed Google Scholar
• Bernards, R. & Weinberg, R. A. A progression puzzle. Nature 418, 823 (2002).
  Article CAS PubMed Google Scholar
• Hellman, S. & Harris, J. R. in Diseases of the Breast (eds Harris, J. R., Lippman, M. E., Morrow, M. & Osborne, C. K.), 407–423 (Lippincott Williams & Wilkins, Philadelphia, 2000). Describes the clinical behaviour of untreated breast cancer, including the incidences of regional lymph-node and distant metastasis.
  Google Scholar
• Tavassoli, F. A. & Devilee, P. (eds) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. (IARC press, Lyon, 2003).
  Google Scholar
• Lee, Y. T. Breast carcinoma: pattern of metastasis at autopsy. J. Surg. Oncol. 23, 175–180 (1983).
  Article CAS PubMed Google Scholar
• Page, D. L. Prognosis and breast cancer. Recognition of lethal and favourable prognostic types. Am. J. Surg. Pathol. 15, 334–349 (1991).
  Article CAS PubMed Google Scholar
• Koscielny, S. et al. Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br. J. Cancer 49, 709–715 (1984).
  Article CAS PubMed PubMed Central Google Scholar
• Rosen, P. P., Groshen, S., Saigo, P. E., Kinne, D. W. & Hellman, S. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J. Clin. Oncol. 7, 1239–1251 (1989).
  Article CAS PubMed Google Scholar
• Carter, C. L., Allen, C. & Henson, D. E. Relation of tumour size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63, 181–187 (1989).
  Article CAS PubMed Google Scholar
• Elston, C. W. & Ellis, I. O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19, 403–410 (1991).
  Article CAS PubMed Google Scholar
• Pinder, S. E. et al. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 24, 41–47 (1994).
  Article CAS PubMed Google Scholar
• de Mascarel, I. et al. Obvious peritumoural emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. Eur. J. Cancer 34, 58–65 (1998).
  Article CAS PubMed Google Scholar
• Hellman, S. Karnofsky Memorial Lecture. Natural history of small breast cancers. J. Clin. Oncol. 12, 2229–2234 (1994).
  Article CAS PubMed Google Scholar
• James, J. J. et al. Bone metastases from breast carcinoma: histopathological–radiological correlations and prognostic features. Br. J. Cancer 89, 660–665 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Borst, M. J. & Ingold, J. A. Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery 114, 637–641 (1993).
  CAS PubMed Google Scholar
• Arpino, G., Bardou, V. J., Clark, G. M. & Elledge, R. M. Infiltrating lobular carcinoma of the breast: tumour characteristics and clinical outcome. Breast Cancer Res. 6, R149–R156 (2004).
  Article PubMed PubMed Central Google Scholar
• McGuire, W. L. & Clark, G. M. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N. Engl. J. Med. 326, 1756–1761 (1992).
  Article CAS PubMed Google Scholar
• Hayes, D. F. et al. Tumour marker utility grading system: a framework to evaluate clinical utility of tumour markers. J. Natl Cancer Inst. 88, 1456–1466 (1996).
  Article CAS PubMed Google Scholar
• Ransohoff, D. F. Bias as a threat to the validity of cancer molecular-marker research. Nature Rev. Cancer 5, 142–149 (2005).
  Article CAS Google Scholar
• Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 (1987).
  Article CAS PubMed Google Scholar
• Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
  Article CAS PubMed Google Scholar
• Ross, J. S. et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8, 307–325 (2003).
  Article CAS PubMed Google Scholar
• Yamauchi, H., Stearns, V. & Hayes, D. F. When is a tumour marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J. Clin. Oncol. 19, 2334–2356 (2001).
  Article CAS PubMed Google Scholar
• Ross, J. S. et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol. Cell Proteomics 3, 379–398 (2004).
  Article CAS PubMed Google Scholar
• Dvorak, H. F. Tumours: wounds that do not heal. Similarities between tumour stroma generation and wound healing. N. Engl. J. Med. 315, 1650–1659 (1986).
  Article CAS PubMed Google Scholar
• Ring, A., Smith, I. E. & Dowsett, M. Circulating tumour cells in breast cancer. Lancet Oncol. 5, 79–88 (2004).
  Article PubMed Google Scholar
• Stathopoulou, A. et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J. Clin. Oncol. 20, 3404–3412 (2002).
  Article CAS PubMed Google Scholar
• Zach, O., Kasparu, H., Wagner, H., Krieger, O. & Lutz, D. Prognostic value of tumour cell detection in peripheral blood of breast cancer patients. Acta Med. Austriaca 59, 32–34 (2002).
  CAS Google Scholar
• Pierga, J. Y. et al. Clinical significance of immunocytochemical detection of tumour cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin. Cancer Res. 10, 1392–1400 (2004).
  Article CAS PubMed Google Scholar
• Diel, I. J. et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J. Natl Cancer Inst. 88, 1652–1658 (1996).
  Article CAS PubMed Google Scholar
• Landys, K., Persson, S., Kovarik, J., Hultborn, R. & Holmberg, E. Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: results of a 20-year median follow-up. Breast Cancer Res. Treat. 49, 27–33 (1998).
  Article CAS PubMed Google Scholar
• Braun, S. et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N. Engl. J. Med. 342, 525–533 (2000).
  Article CAS PubMed Google Scholar
• Wiedswang, G. et al. Detection of isolated tumour cells in bone marrow is an independent prognostic factor in breast cancer. J. Clin. Oncol. 21, 3469–3478 (2003).
  Article CAS PubMed Google Scholar
• Molino, A. et al. Bone marrow micrometastases in 109 breast cancer patients: correlations with clinical and pathological features and prognosis. Breast Cancer Res. Treat. 42, 23–30 (1997).
  Article CAS PubMed Google Scholar
• Ismail, M. S. et al. Detection of micrometastatic disease and monitoring of perioperative tumour cell dissemination in primary operable breast cancer patients using real-time quantitative reverse transcription-PCR. Clin. Cancer Res. 10, 196–201 (2004).
  Article CAS PubMed Google Scholar
• Gebauer, G., Fehm, T., Merkle, E., Jaeger, W. & Mitze, M. Micrometastases in axillary lymph nodes and bone marrow of lymph node-negative breast cancer patients — prognostic relevance after 10 years. Anticancer Res. 23, 4319–4324 (2003).
  PubMed Google Scholar
• Funke, I. & Schraut, W. Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. J. Clin. Oncol. 16, 557–566 (1998).
  Article CAS PubMed Google Scholar
• Fidler, I. J. Metastasis: quantitative analysis of distribution and fate of tumour embolilabeled with 125 I-5-iodo-2′-deoxyuridine. J. Natl Cancer Inst. 45, 773–782 (1970).
  CAS PubMed Google Scholar
• Gangnus, R., Langer, S., Breit, E., Pantel, K. & Speicher, M. R. Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin. Cancer Res. 10, 3457–3464 (2004).
  Article CAS PubMed Google Scholar
• Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983–3988 (2003). Describes the prospective isolation of candidate breast tumour stem cells and their ability to form tumours in mice.
  Article CAS PubMed PubMed Central Google Scholar
• Gudjonsson, T. et al. Isolation, immortalization, and characterization of a human breast epithelial cell line with stem cell properties. Genes Dev. 16, 693–706 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Clarke, R. B. et al. A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev. Biol. 277, 443–456 (2005).
  Article CAS PubMed Google Scholar
• Andreasen, P. A., Kjoller, L., Christensen, L. & Duffy, M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 72, 1–22 (1997).
  Article CAS PubMed Google Scholar
• Umeda, T., Eguchi, Y., Okino, K., Kodama, M. & Hattori, T. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. J. Pathol. 183, 388–397 (1997).
  Article CAS PubMed Google Scholar
• Janicke, F., Schmitt, M. & Graeff, H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin. Thromb. Hemost. 17, 303–312 (1991).
  Article CAS PubMed Google Scholar
• Bajou, K. et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoural angiogenesis and growth. Oncogene 23, 6986–6990 (2004).
  Article CAS PubMed Google Scholar
• Foekens, J. A. et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 60, 636–643 (2000).
  CAS PubMed Google Scholar
• Konecny, G. et al. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clin. Cancer Res. 7, 2448–2457 (2001).
  CAS PubMed Google Scholar
• Janicke, F. et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J. Natl Cancer Inst. 93, 913–920 (2001).
  Article CAS PubMed Google Scholar
• Harbeck, N., Kates, R. E. & Schmitt, M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J. Clin. Oncol. 20, 1000–1007 (2002).
  Article PubMed Google Scholar
• Look, M. P. et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl Cancer Inst. 94, 116–128 (2002). Confirms the prognostic value of uPA and PAI1 in primary breast cancer in a re-analysis of independent patient data provided by the members of the EORTC Receptor and Biomarker Group.
  Article CAS PubMed Google Scholar
• Harbeck, N. et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res. 62, 4617–4622 (2002).
  CAS PubMed Google Scholar
• Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000). Classifies primary breast tumours into 5 subtypes on the basis of similarities in their gene-expression patterns.
  Article CAS PubMed Google Scholar
• Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869–10874 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Sorlie, T. et al. Repeated observation of breast tumour subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100, 8418–8423 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Egeblad, M. & Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev. Cancer 2, 161–174 (2002).
  Article CAS Google Scholar
• Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S. & Senn, H. J. Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer. J. Clin. Oncol. 19, 3817–3827 (2001).
  Article CAS PubMed Google Scholar
• Tuma, R. S. A big trial for a new technology: TransBIG project takes microarrays into clinical trials. J. Natl Cancer Inst. 96, 648–689 (2004).
  Article PubMed Google Scholar
• Wang, Y. et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671–679 (2005).
  Article CAS PubMed Google Scholar
• Tan, P. K. et al. Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res. 31, 5676–5684 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Huang, E. et al. Gene expression predictors of breast cancer outcomes. Lancet 361, 1590–1596 (2003).
  Article CAS PubMed Google Scholar
• Ma, X. J. et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5, 607–616 (2004).
  Article CAS PubMed Google Scholar
• Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817–2826 (2004).
  Article CAS PubMed Google Scholar
• Esteva, F. J. et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin. Cancer Res. 11, 3315–3319 (2005).
  Article CAS PubMed Google Scholar
• Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537–549 (2003).
  Article CAS PubMed Google Scholar
• Minn, A. J. et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumours. J. Clin. Invest. 115, 44–55 (2005). Shows that organ-specific metastasis of a breast cancer cell line is determined by the poor-prognosis signature and an additional metastasis-specific gene set.
  Article CAS PubMed PubMed Central Google Scholar
• Chang, H. Y. et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumours and wounds. PLoS Biol. 2, E7 (2004).
  Article PubMed PubMed Central CAS Google Scholar
• Chang, H. Y. et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl Acad. Sci. USA 102, 3738–3743 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Ein-Dor, L., Kela, I., Getz, G., Givol, D. & Domany, E. Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 21, 171–178 (2005).
  Article CAS PubMed Google Scholar
• Fidler, I. J. Selection of successive tumour lines for metastasis. Nature New Biol. 242, 148–149 (1973).
  Article CAS PubMed Google Scholar
• Leighton, J. Inherent malignancy of cancer cells possibly limited by genetically differing cells in the same tumour. Acta Cytol. 9, 138–140 (1965).
  Google Scholar
• Stackpole, C. W. Distinct lung-colonizing and lung-metastasizing cell populations in B16 mouse melanoma. Nature 289, 798–800 (1981).
  Article CAS PubMed Google Scholar
• Vaage, J. Metastasizing potentials of mouse mammary tumours and their metastases. Int. J. Cancer 41, 855–858 (1988).
  Article CAS PubMed Google Scholar
• Eccles, S. A., Heckford, S. E. & Alexander, P. Effect of cyclosporin A on the growth and spontaneous metastasis of syngeneic animal tumours. Br. J. Cancer 42, 252–259 (1980).
  Article CAS PubMed PubMed Central Google Scholar
• Weiss, L., Holmes, J. C. & Ward, P. M. Do metastases arise from pre-existing subpopulations of cancer cells? Br. J. Cancer 47, 81–89 (1983).
  Article CAS PubMed PubMed Central Google Scholar
• Hill, R. P., Chambers, A. F., Ling, V. & Harris, J. F. Dynamic heterogeneity: rapid generation of metastatic variants in mouse B16 melanoma cells. Science 224, 998–1001 (1984).
  Article CAS PubMed Google Scholar
• Ling, V., Chambers, A. F., Harris, J. F. & Hill, R. P. Quantitative genetic analysis of tumour progression. Cancer Metastasis Rev. 4, 173–192 (1985).
  Article CAS PubMed Google Scholar
• Kerbel, R. S., Waghorne, C., Man, M. S., Elliott, B. & Breitman, M. L. Alteration of the tumorigenic and metastatic properties of neoplastic cells is associated with the process of calcium phosphate-mediated DNA transfection. Proc. Natl Acad. Sci. USA 84, 1263–1267 (1987).
  Article CAS PubMed PubMed Central Google Scholar
• Kerbel, R. S., Waghorne, C., Korczak, B., Lagarde, A. & Breitman, M. L. Clonal dominance of primary tumours by metastatic cells: genetic analysis and biological implications. Cancer Surv. 7, 597–629 (1988).
  CAS PubMed Google Scholar
• Garcia-Olmo, D., Garcia-Olmo, D. C., Ontanon, J., Martinez, E. & Vallejo, M. Tumour DNA circulating in the plasma might play a role in metastasis. The hypothesis of the genometastasis. Histol. Histopathol. 14, 1159–1164 (1999).
  CAS PubMed Google Scholar
• Garcia-Olmo, D. & Garcia-Olmo, D. C. Functionality of circulating DNA: the hypothesis of genometastasis. Ann. NY Acad. Sci. 945, 265–275 (2001).
  Article CAS PubMed Google Scholar
• Lancaster, M., Rouse, J. & Hunter, K. W. Modifiers of mammary tumour progression and metastasis on mouse chromosomes 7, 9, and 17. Mamm. Genome 16, 120–126 (2005).
  Article CAS PubMed Google Scholar
• Bissell, M. J. & Radisky, D. Putting tumours in context. Nature Rev. Cancer 1, 46–54 (2001).
  Article CAS Google Scholar
• Bhowmick, N. A., Neilson, E. G. & Moses, H. L. Stromal fibroblasts in cancer initiation and progression. Nature 432, 332–337 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Weigelt, B. et al. Gene expression profiles of primary breast tumours maintained in distant metastases. Proc. Natl Acad. Sci. USA 100, 15901–15905 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Ma, X. J. et al. Gene expression profiles of human breast cancer progression. Proc. Natl Acad. Sci. USA 100, 5974–5979 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Schmidt-Kittler, O. et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc. Natl Acad. Sci. USA 100, 7737–7742 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105–111 (2001).
  Article CAS PubMed Google Scholar
• Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396–401 (2004).
  Article CAS PubMed Google Scholar
• Bissell, M. J. & Labarge, M. A. Context, tissue plasticity, and cancer; are tumour stem cells also regulated by the microenvironment? Cancer Cell 7, 17–23 (2005).
  CAS PubMed PubMed Central Google Scholar
• Dontu, G., El-Ashry, D. & Wicha, M. S. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol. Metab. 15, 193–197 (2004).
  Article CAS PubMed Google Scholar
• Chang, J. C. et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362–369 (2003).
  Article CAS PubMed Google Scholar
• Ayers, M. et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J. Clin. Oncol. 22, 2284–2293 (2004).
  Article CAS PubMed Google Scholar
• Quackenbush, J. Computational analysis of microarray data. Nature Rev. Genet. 2, 418–427 (2001).
  Article CAS PubMed Google Scholar
• Eisen, M. B., Spellman, P. T., Brown, P. O. & Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl Acad. Sci. USA 95, 14863–14868 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Golub, T. R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531–537 (1999).
  Article CAS PubMed Google Scholar
• Al-Hajj, M. & Clarke, M. F. Self-renewal and solid tumour stem cells Oncogene 23, 7274–7282 (2004).
  Article CAS PubMed Google Scholar
• Van't Veer, L. J., Weigelt, B. Road map to metastasis. Nature Med. 9, 999–1000 (2003).
  Article CAS PubMed Google Scholar